About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

ZD6474 Phase IIa Dose Finding Multicentre Study | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 2NCT00252746

ZD6474 Phase IIa Dose Finding Multicentre Study

To assess the objective response rates (by RECIST) to ZD6474 100, 200 and 300 mg/day respectively

Lead sponsor: Genzyme, a Sanofi Company•7 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Genzyme, a Sanofi Company

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Provision of written informed consent.
•Life expectancy of 12 weeks or longer.

Exclusion Criteria

•Pregnancy, breast feeding or female patients wishing to become pregnant.
•Treatment with a non-approved or investigational drug within 30 days before enrolment

Related studies

RECRUITINGPhase 1/2

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

NCT06772623 · Non Small Cell Lung Carcinoma

Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations

NCT07369596 · Non Small Cell Lung Carcinoma NSCLC

Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.

NCT00759382 · Non Small Cell Lung Carcinoma

TERMINATEDPhase 2

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

NCT00592007 · Non Small Cell Lung Carcinoma

COMPLETEDPhase 1

Phase I Study of Vorinostat and Sorafenib in Advanced Cancer

NCT00635791 · Malignant Solid Tumour, Renal Cell Carcinoma, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 25, 2016Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment53

Start dateDec 2004

Last updatedAug 25, 2016

Condition

Non Small Cell Lung Carcinoma

Locations shown

Research Site

Matsuyama, Ehime

Research Site

Isehara, Kanagawa

Research Site

Okayama, Okayama-ken

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 25, 2016Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions